luspatercept

BMS, Acceleron blood cancer drug to undergo FDA expert panel review

The companies said the FDA's Oncologic Drugs Advisory Committee would review their application for Reblozyl in myelodysplastic syndrome. The drug, which won approval for a blood disorder last month, was developed under a partnership between Acceleron and Celgene, which BMS has since acquired.

By Alaric DeArment

BioPharma

Celgene, Acceleron file for approval of blood disease drug luspatercept

Approval of luspatercept in myelodysplastic syndrome and beta-thalassemia is expected in April 2020, or as early as December of this year if it receives FDA priority review, an analyst wrote.

By Alaric DeArment